Dural Graft Market Size, Share, Growth, and Regional Forecast, 2025 to 2032

The global dural graft market size is valued at US$887.2 million in 2025 and is projected to reach US$1,307.8 million, growing at a CAGR of 5.7% during the forecast period from 2025 to 2032.

The global dural graft industry is growing steadily, driven by demand for safe and durable dural repair solutions. North America leads due to advanced neurosurgical infrastructure and high adoption of innovative grafts. Asia Pacific is the fastest-growing market, supported by expanding neurosurgery centers, rising healthcare investments, and collaborations between regional hospitals and global medical device providers.

• Dominant Product Type: Xenogeneic dural grafts hold about 35.4% share, driven by their proven biocompatibility, ease of handling, and effectiveness in neurosurgical repair, supporting widespread clinical adoption.
• Dominant Region: North America accounts for roughly 39.5% of global revenue, driven by advanced neurosurgical infrastructure, high adoption of innovative graft materials, and strong hospital networks.
• Investment Plans: Asia Pacific is the fastest-growing region, fueled by expanding neurosurgery centers, rising awareness of advanced graft options, government healthcare initiatives, and collaborations between local hospitals and global medical device firms.
• Market Drivers: Rising neurosurgical procedures, increasing preference for safe and durable grafts, innovation in biomaterials, and growing hospital investments.
• Market Opportunity: Development of next-generation synthetic and bioengineered grafts, localized manufacturing, integration with minimally invasive surgical tools, and expansion into emerging markets with rising healthcare access.

Driver - Rising Incidence of Neurological Disorders and Increasing Awareness about Neurological Conditions

Neurological illnesses constitute a significant component of the global disease burden and are an important and growing global health issue. According to a study published in Frontiers (2022) on the international, regional, and national burden and associated risk factors of neurological illnesses, there were 349 million DALYs and over 10 million fatalities worldwide in 2019 as a result of neurological disorders. Stroke was the leading cause of DALYs among the 18 neurological illnesses.

The Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022-2031 was adopted on May 27, 2022, by the 75th World Health Assembly (IGAP). By establishing the IGAP, WHO has vowed to give brain health top priority over the following ten years.

Given that neurological illnesses are the primary cause of disability and the second greatest cause of death worldwide, this action is both overdue and essential. As a result, the rising prevalence of neurological disorders, as well as increased awareness of neurological illnesses, are driving the dural graft market.

Restraints - Lack of Skilled Neurosurgeon Workers

A shortage of skilled neurosurgical workforce is a significant restraint on the dural graft market. Globally, there are only ~49,940 neurosurgeons, with a highly uneven distribution: the median density is just 3.56 neurosurgeons per million people, and 33 countries reportedly have zero neurosurgeons.

The shortage is especially acute in low- and middle-income regions: for example, in Africa, there may be as few as 0.11 neurosurgeons per 100,000 population, compared to much higher densities in high-income countries. According to global estimates, approximately 23,300 more neurosurgeons would be needed just to meet essential surgical case demand each year, suggesting a massive capacity gap.

This limited workforce constrains the adoption and expansion of dural graft technologies, especially in underserved markets.

Opportunity - Next-Generation Synthetic Grafts

Next-generation synthetic dural grafts are clinically relevant because current data show nontrivial complication rates with existing materials: for instance, a large multicenter pediatric study found that synthetic grafts had higher complication rates than autograft after posterior-fossa decompression (33.9% vs 28.7%).

A systematic review of CSF leakage after duraplasty in infratentorial surgery reported leak rates for non-autologous grafts ranging from 0% to 25%, with most studies clustering between 3% and 15%. Moreover, a meta-analysis of 1,877 patients showed that non-autologous grafts (including synthetic grafts) had a CSF leakage rate of ~5.9%, compared with 4.4% for autologous grafts.

In one institutional series, use of a non-sutureable collagen matrix graft resulted in a 10% CSF leak rate and 6.7% pseudomeningocele incidence. These figures highlight a clear clinical need: synthetic grafts that can reduce leak and reoperation risk would meaningfully improve patient outcomes.

By Product, Xenogeneic Dural Graft Dominates the Dural Graft Market

Xenogeneic Dural Graft occupied 35.4% share of the global market in 2025. The clinical results of duraplasty employing xenogeneic grafts have been similar and successful. The complex study of xenogeneic fascia, pericardium, and dura mater grafts used for duraplasty in neurosurgery over the past 20 years found them to be highly effective, with a success rate of 96.9%.

By Application, Traumatic Brain and Spine Injury is gaining traction due to rising TBI in older adults, and the global demand for brain and spine surgeries is increasing.

The Traumatic Brain and Spine segment accounted for around 51.4% of the total market in 2025. There is a significant public health burden associated with traumatic brain injury (TBI), which has the highest prevalence of all prevalent neurological illnesses.

TBI is becoming more and more well-documented as a chronic disease with long-term effects, including an elevated risk of late-onset neurodegeneration, in addition to an acute condition. The age group between 65 and 74 years old has the highest rate of TBI hospital admissions, followed by children and teenagers. TBI rates among older adults are rising and, in certain nations, outpace population growth.

Consequently, the growing geriatric population in the world demands traumatic brain and spine surgeries.

North America Dural Graft Market Trends

North America accounted for around 39.5% market share in the global market in 2024.

Compared to all other age groups in the U.S., older persons are more likely to require hospitalization and pass away from a TBI. However, because TBI symptoms coincide with those of other medical illnesses that are frequent in older persons, such as dementia, TBIs may be ignored or incorrectly diagnosed in older adults.

• The Centers for Disease Control and Prevention estimated that over 64,000 Americans would die in 2020 as a result of TBI. 3 That equates to around 176 fatalities from TBI per day.

As a result, more Americans are being diagnosed with these medical issues, which is driving up demand.

Europe Dural Graft Market Trends

Europe is a strategically important region in the dural graft market because of its high burden of traumatic brain injury (TBI) and well-developed neurosurgical infrastructure. Across the EU, there are around 1.45 million TBI hospital admissions per year, with an age-adjusted rate of roughly 287 hospitalizations per 100,000 people. Mortality from TBI in Europe stands at about 11.7 per 100,000, based on pooled data.

The annual in-hospital healthcare costs for TBI in Europe are substantial, particularly for severe cases; costs per patient can reach €355,000, depending on injury severity. This large and growing TBI patient population, combined with the resource intensity of treatment (including duraplasty), makes Europe a key region for the adoption of advanced synthetic dural grafts.

Asia Pacific Dural Graft Market Trends

Due to rapid urbanization, rising road traffic accidents, and expanding healthcare infrastructure across the Asia Pacific, the region is becoming the fastest-growing market for dural grafts. According to the Global Burden of Disease study, East Asia accounted for 4.31 million TBI cases in 2021, of which 69% were moderate to severe.

In Southeast Asia, age-standardized TBI incidence reached 283 per 100,000 in 2016. Moreover, neurological disease burden in Asia is surging; in 2021, Asia recorded 479 million new neurological cases, driven in part by trauma. These statistics point to high unmet need, making the Asia Pacific a major opportunity zone for synthetic, durable dural grafts.

Leading companies in the dural graft market focus on material innovation, biocompatibility, and strategic collaborations. They invest in advanced synthetic materials, improved graft designs, and surgical integration technologies to enhance treatment outcomes, reduce complications, and expand global presence, addressing rising demand for safer, efficient, and patient-specific neurosurgical solutions.

Key Industry Developments:

• In October 2025, Integra LifeSciences spotlighted its neurosurgical product portfolio at the Congress of Neurological Surgeons (CNS) Annual Meeting. The company showcased advanced solutions for dural repair, cranial access, and neurovascular procedures, highlighting innovations that improve surgical precision, patient outcomes, and overall neurosurgical efficiency.
• In September 2025, B. Braun SE acquired True Digital Surgery, expanding its digital surgery capabilities. The acquisition aims to enhance B. Braun’s portfolio with advanced surgical technologies, improve procedural precision, and strengthen its position in the global surgical solutions market. This move reflects the company’s strategic focus on integrating innovative digital solutions into operating room workflows.